ArticleFrontiers in cardiovascular medicine2022

Evolocumab enables rapid LDL-C reduction and inflammatory modulation during in-hospital stage of acute coronary syndrome: A pilot study on Chinese patients.

Ziwei Ou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.